Information Provided By:
Fly News Breaks for May 14, 2019
ICPT, CBAY
May 14, 2019 | 07:14 EDT
Citi analyst Joel Beatty started CymaBay Therapeutics (CBAY) with a Buy rating and $21 price target. The analyst believes the company's seladelpar will "likely dethrone" Intercept Pharmaceuticals' (ICPT) Ocaliva as the top-selling branded primary biliary cholangitis drug. Topline results for seladelpar in PBC are anticipated in 2021 and the analyst sees a 75% probability of approval.
News For CBAY;ICPT From the Last 2 Days
There are no results for your query CBAY;ICPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.